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Growing population of advanced heart failure patients represents one of the major burden
for health care system. Heart transplantation is the gold standard for a severe HF but
contraindications and lack of donors are ultimate hurdles for its widespread use. Heart
replacement using durable mechanical circulatory support, e.g. continuous-ﬂow left ventri-
cular assist devices (LVAD), has grown fast in recent years. It is reasonable to assume that the
number of LVAD implantations will continue to grow and will soon exceed the number of
HTx. The review is intended to provide essential information on the results of clinical trials
with continuous ﬂow left ventricular assist devices, indications and implantation timing.
General and speciﬁc risks of LVAD surgery, short and long term courses are described, and risk
assessment is outlined.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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The number of heart failure (HF) patients still grows, and it is
estimated that HF affects around 10 million adult people across
USA and Europe. Of these, about 10% are in advanced stage
described as stage D according to ACC/AHA classiﬁcation [1,2].ch Society of Cardiology.
.
skStage D patients are patients with severe left ventricular
dysfunction who experience symptoms at rest or with mild
exertion despite maximal therapy. These patients have poor
prognosis, need repeated hospitalizations and if they do not
die suddenly the disease progresses to refractory and terminal
phase. Optimal or maximal medical and device managementPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
Fig. 1 – Primary left ventricular assist device (LVAD) patient
enrollment in the Interagency Registry for Mechanically
Assisted Circulatory Support (INTERMACS) database from
June 23, 2006, to June 30, 2011, stratiﬁed by device type and
implant year. RVAD, left ventricular assist device; TAH, total
artiﬁcial heart (according to Ref. [4]).
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 7 7 – e 3 8 2e378includes salt and ﬂuid restriction, use of ACE inhibitors or
angiotensin receptor blockers, beta-blockers, diuretics and
aldosterone antagonists. Ivabradin was shown to be useful in
patients with sinus rhythm and digoxin could be a reasonable
in those with atrial ﬁbrilation. In selected cases implantable
cardioverter-deﬁbrillators (ICDs) and/or cardiac resynchroniza-
tion are indicated.
With disease progression tolerance of vasodilators decreases
and other therapies that should be considered include heart
transplantation, chronic inotropes, permanent mechanical sup-
port, and experimental surgery or medications, depending on
the individual patient presentation and preference. Majority of
patients nowadays need palliative end of live care.
Heart transplantation (HTx) is the gold standard for a
severe HF but contraindications and lack of donors are major
hurdles for its widespread use. Heart replacement using
durable mechanical circulatory support, e.g. continuous-
ﬂow left ventricular assist devices (LVAD), has grown fast in
recent years (Fig. 1) [3]. It is reasonable to assume that the
number of LVAD implantations will continue to grow and will
soon exceed the number of HTx.Fig. 2 – Heart Mate II LVAD.2. LVAD implantation results overview
The ﬁrst and only randomized controlled trial of an implan-
table LVAD in patients with stage D heart failure (The
Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure Trial) compared med-
ical therapy with the pulsatile Heartmate XVE. The trial
showed a one year survival of 52% in implanted patients in
comparison to 25% of pts. on medical therapy [4]. This trial
led to FDA approval of Heartmate XVE for destination therapy
(DT) as lifetime support. Relatively high postoperative mor-
tality and high rate of post-implant complications limited the
expanded use of pulsatile devices.
New era for LVAD started after the introduction of new
generation on pumps, the continuous-ﬂow devices (CF LVAD).Continuous-ﬂow based pumps, signiﬁcantly reduce size
and weight compared with implantable pulsatile pumps.
Continuous-ﬂow LVADs are also silent, create minimal motion
and vibration, provide greater patient comfort, enhance the
quality of life, and reduce the risk of infection. Continuous-
ﬂow LVADs use centrifugal ﬂow or axial ﬂow blood pumps.
The fundamental design characteristic of both types of pumps
is that they have a single moving component, the impeller.
Pumps can produce up to 10 l/min ﬂow. Flow is regulated by
impeller speed but is signiﬁcantly load dependent and can be
effectively adjusted by changes in preload and afterload [5].
The pump is connected with a percutaneous lead to an
external controller and batteries worn by the patient (Fig. 2).
In a prospective multicenter study of 133 heart transplant
candidates to whom CF LVAD (Heart Mate II) was implanted
[6], has shown survival rate of 75% during support at 6
months and 68% at 12 months. This study was followed by
an updated report with a total of 281 bridge to transplant
(BTT) patients. Actuarial survival on support was 72% at 18
months [7].
A clinical trial for destination therapy (DT) in transplanta-
tion ineligible patients has also been completed [8]. In this trial
134 pts. were assigned to CF LVAD (Heart Mate II) and 66 to
approved pulsatile ﬂow devices. The primary composite end-
point was survival free from disabling stroke and reoperation
to repair or replace the device at 2 years. This endpoint was
achieved by 46% of patients from the CF device group and only
11% from pulsatile ﬂow. Two years survival rate was 58% (CF)
vs. 24% (pulsatile). The trial has led to FDA approval of LVAD
Heart mate II to be used as DT. Post-approval studies continued
to prove superiority of Heart Mate II LVAD above pulsatile ﬂow
devices in BTT [9,10] and also DT setting [11]. In DT one year
survival improved from 68% to 73% [11]. Several European
centers reported similar results [12,13]. During recent years
new generation of CF ﬂow pump with centrifugal design were
introduced to clinical use. The only moving part, an impeller, is
suspended by passive magnetic and hydrodynamic thrust
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could be placed intrapericardially. In the clinical study by
Aaronson [14] 140 heart transplant candidates received cen-
trifugal pumps and the post-implant course was compared
with that of patients implanted contemporaneously with
commercially available devices. The primary outcome, success,
was deﬁned as survival on the originally implanted device,
transplantation, or explantation for ventricular recovery at 180
days. Success occurred in 90.7% of investigational pump
patients and 90.1% of controls, establishing the noninferiority
of the investigational pump. This large study conﬁrmed posi-
tive results of a smaller series of the device implantations
performed previously in Europe and Australia [15,16]. There are
several other centrifugal CF devices tested in clinical trials. The
DuraHeart (Terumo Heart Inc., Ann Arbor, MI) an implantable
centrifugal ﬂow device has been shown to provide reliable
support as a BTT device in a multicenter European trial, with a
77% survival rate at 1 year [17].
Continuous ﬂow LVAD improve not only very poor prog-
nosis of advanced heart failure patients but also the quality
of life. Analysis of pooled data from BTT and DT trials of more
than 600 patients implanted with Heart Mate II LVAD has
shown that 82% (BTT) and 80% (DT) of patients at 6 months
and 79% (DT) at 24 months moved to NYHA functional class I
or II [18].
In the recent Guidelines for the diagnosis and treatment of
acute and chronic heart failure, European Society of Cardiology
recognized a growing role of LVAD in the treatment of
terminal HF in selected group of patients [2]. According the
Guidelines an LVAD is recommended in selected patients with
end-stage HF despite optimal pharmacological and device
treatment who are otherwise suitable for heart transplanta-
tion, to improve symptoms and reduce the risk of HF hospi-
talization for worsening HF and to reduce the risk of
premature death while awaiting transplantation (class I, level
of evidence B). An LVAD should be considered in highly
selected patients who have end-stage HF despite optimalFig. 3 – Actuarial survival for primary left ventricular assist
device (LVAD) implants, stratiﬁed by continuous-ﬂow
pumps (CFP) vs. pulsatile-ﬂow pumps (PFP). INTERMACS,
Interagency Registry for Mechanically Assisted Circulatory
Support; RVAD, right ventricular assist device (according to
Ref. [4]).pharmacological and device therapy and who are not suitable
for heart transplantation, but are expected to survive longer
than 1 year with good functional status, to improve symptoms,
and reduce the risk of HF hospitalization and of premature
death (class IIa, level of evidence B).
These decisions are highly supported by recently pub-
lished report of INTERMACS registry. This report documents
that in actual clinical practice current actuarial survival with
continuous-ﬂow pumps exceeds 80% at 1 year and 70% at 2
years [3] (Fig. 3).3. LVAD indication and timing
From the point of view of general treatment goals there are
three indications accepted for durable LVAD: (1) bridge to
transplantation (BTT), (2) bridge to candidacy (BTC) and (3)
destination therapy (DT).
BTT means LVAD is implanted to bridge critical deteriora-
tion of clinical condition and hemodynamic in a patient listed
for HTx, while waiting for donor. Bridge to candidacy is the
term used to describe the situation when LVAD is used in a
patient who is not initially eligible for transplantation for a
variety of reasons. The most common are pulmonary hyper-
tension, renal dysfunction or obesity considered as contra-
indications for HTx. These contraindications are expected to
resolve after a period of successful mechanical circulatory
support. DT refers to a condition when LVAD is a permanent
therapy for terminal systolic heart failure.
Proper candidate selection and timing of implantation is
critical for a successful surgery and long term outcome. Patients
are evaluated to determine appropriateness for LVAD implan-
tation based on the evaluation of the short term prognosis and
ability to successfully undergo the operative procedure. Very
important for a long-term success is also to assess patient
psychosocial conditions, his/her ability to cope the new life
situation and reality of adequate family/caregiver support.
First question to address in consideration of durable LVAD
is potential of reversibility of heart failure and/or factors that
could contribute to its worsening. Temporary circulatory sup-
port can be used for patient stabilization and next decision on
optimal therapy (bridge to decision). Durable LVAD should only
be considered in patients whose ventricular function cannot
recover and who are not able to maintain hemodynamic and
vital organ function. A range of referral criteria assessments
and scoring systems can be utilized to deﬁne the right moment
to screen a patient for a LVAD implant.
Appropriate timing for referral is when a patient presents
with Class IIIB or IV heart failure and several risk factors for
bad short term outcome occur. Beside severe physical limita-
tion these patients are characterized with hypotension, intol-
erance to ACE inhibitor, angiotensin receptor blockers, and/or
beta-blockers and need high diuretic dose for relieving conges-
tion (more than 240mg of furosemide) [2]. Laboratory assess-
ment usually demonstrates abnormalities reﬂecting end organ
congestion and hypoperfusion as hyponatremia, increase in
BUN and serum creatinin, bilirubin and INR. To reduce the risk
of LVAD implantation patients should be referred at a time
when the ﬁrst signs of vital organ dysfunction/lesion appear
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signs of cerebral hypoperfusion).4. General and speciﬁc risk assessment
The Interagency Registry for Mechanically Assisted Circula-
tory Support (INTERMACS) has classiﬁed patients treated
with VAD therapy into seven categories based on clinical
proﬁle at the time of implantation (Table 1). The current 6-
month survival data for patients receiving pulsatile LVADs
indicates that patients in proﬁle 1, cardiogenic shock
(“crushed and burn”), have the worst survival, and those in
proﬁle 3 (“stable on inotropes”) have the best survival. These
data demonstrate that patients with cardiogenic shock are in
too bad of a condition to survive surgery needed for perma-
nent LVAD support. Thus, for these patients, better option is
to stabilize them using one of the less invasive temporary
percutaneous or surgically placed support systems. Accord-
ing the last INTERMACS Report (4) the dominant risk factors
during the early period are patients in INTERMACS Level 1
(cardiogenic shock) and patients with severe right ventricular
failure sufﬁcient to require biventricular support. Lietz et al.
[19] analyzed pre-operative data from 222 patients who
received pulsatile device and established a risk scoring
system for post implant survival. Multivariate analysis pro-
vided 9 risk factors for 90-day mortality (Table 2). Score of
more than 17 or more than 19 was classiﬁed as risk categories
with high or very high risk of death. Recently more simpleTable 1 – INTERMACS classiﬁcation.
1. “Critical cardiogenic shock” (patient has life-threatening hypotensi
pressor support; “crushed and burn”)
2. “Progressive decline” (patient has been demonstrated “dependent
deterioration)
3. “Stable but inotrope-dependent” (patient is clinically stable on m
circulatory support device, after repeated documentation of failur
4. “Resting symptoms” (patient is at home on oral therapy but frequ
living)
5. “Exertion intolerant” (patient is comfortable at rest but unable to
household)
6. “Exertion limited” (patient is comfortable at rest without evidence
7. “Advanced NYHA class III” (patient is clinically stable with a reas
decompensation)
Table 2 – Risk factors for 90-day mortality and the weighted s
Risk factor
Platelet count o148 106/l
Serum albumin o33 g/l
International normalization ratio 41.1
Vasodilator therapy
Mean pulmonary artery pressures o25 mmHg
Aspartate aminotransferase 445 U/ml
Hematocrit o34%
Blood urea nitrogen 451 mg/dl
No intravenous inotropesapproach has shown to be useful for the postoperative risk
prediction. MELD score is used to predict events in cirrhotic
subjects undergoing major surgery and for its calculation
only levels of serum creatinine, bilirubin and INR are needed
[20,21]. Odds ratios, measuring the ability of MELD score to
predict perioperative mortality, were 1.5 (95% conﬁdence
interval, 1.1–2.0) per 5 MELD units for INTERMACS cohorts.
In patients with MELD score ≥17 in comparison with those
where score was o17, risk-adjusted Cox proportional-hazard
ratios for 6-month mortality were 2.5.
Right ventricular failure (RVF) after LVAD implantation
represents a major challenge to the successful application of
continuous-ﬂow devices. Incidence of RVF varies between
13% and 44%, which most likely depends on the different
deﬁnitions of the RVF at the various implant centers. There
are a lot of studies aiming to deﬁne predictors of RVF after
LVADs implantation. Patients with higher risk of RVF are
females [4,22], have heart failure of nonischemic etiology [4],
preoperative ventilatory or mechanical circulatory support
[19,23]. They are characterized with increased level of bilir-
ubin, creatinine, BUN and high spontaneous INR [22,23]. High
central venous pressure, transpulmonary gradient, low right
ventricular stroke work index and cardiac index and high
CVP/PCW ratio (40.63) were identiﬁed as signiﬁcant hemo-
dynamic risk factors of RVF [24,25]. Echocardiographic sings
of high risk are severe tricuspid regurgitation, low TAPSE
(o7.5 mm), RV short to long axis ≥0.6, right to left short axis
diameter ≥0.72, and corrected tricuspid regurgitation dura-
tion ≥461 ms [26–31].on and profound low cardiac output with rapidly escalating inotropic
” on inotropic support but nonetheless shows signs of continuing
ild-moderate doses of intravenous inotropes, or has a temporary
e to wean without symptoms)
ently has symptoms of congestion at rest or with activities of daily
engage in any activity, living predominantly within the house or
of ﬂuid overload, is able to do some mild activity)
onable level of comfortable activity, despite history of previous
cores (according Ref. [19]).
Score
7
5
4
4
3
2
2
2
2
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surgery have intrinsically poor right ventricle with low prob-
ability of recovery and syndrome of low cardiac index and
splanchnic congestion. There is an effort to formulate pre-
dictive models based on scoring systems [19,22–24] but
validation and reproducibility of these scoring systems seems
to be questionable [32].5. Pre-implant management/optimization
Patient management before LVAD implantation needs indi-
vidual consideration and recognition of the risk of adverse
postoperative outcome. Measures to optimize preoperative
condition and prevent complications are, therefore, needed.
Time frame for these measures takes hours for patients
appeared in the INTERMACS 1-2 class or days up to weeks for
patients in the INTERMACS 3-4 class. Management targets
and treatment goals are individual and there are no control
studies on preparation and optimization of a patient for
LVAD surgery. Recommendations are based on observational
studies and transformation of experience from general acute
cardiac care and cardiac surgery. There are several areas for
therapeutic and preventive intervention. Most important are
infection prevention, nutritional intervention, measures aimed
to improve hemodynamics and right ventricular function, to
enhance renal and hepatic function, normalize coagulation
and blood count [5,33]. Immediate preoperative assessment
and optimization is in the hands of a dedicated team and a
more detailed description of each step in preparing a patient
for surgery is beyond the scope of this article.6. Conclusion
A ﬁeld of cardiac replacement using durable continuous ﬂow
left ventricular assist devices experiences rapid expansion in
technology as well as in medical knowledge. We can expect
miniaturization and sophistication of devices, reduction of
perioperative mortality and shifting of indications to less
severe stages of chronic heart failure. All this has increased
and will continue to increase demand for economic and
human capital to support LVAD programs. These programs
appear to be the only viable way to address the growing
population of stage D heart failure patients.
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